Biocon Biologics gets marketing approval for YESAFILI; stock trades ~1% higher

15 Nov 2023 , 11:48 AM

Biocon Biologics, a Biocon subsidiary, stated on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given marketing authorization for YESAFILI, an Aflibercept biosimilar.

This clearance followed the European Commission’s (EC) permission for marketing authorization in the European Union (EU) in September.

YESAFILI, an ophthalmology product, is intended to treat a variety of eye conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).

The biosimilar is highly comparable to the reference medication Eylea® (aflibercept).

At around 11.44 AM, Biocon was trading 1.21% higher at Rs 230.10, against the previous close of Rs 227.35 on NSE. The counter touched an intraday high and low of Rs 231.75 and Rs 228.45, respectively.

For feedback and suggestions, write to us at [e-mail]